Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Retrovirology cung cấp cho các bạn kiến thức về ngành y đề tài: Expression Section in the HIV Drug Resistance Program at the National Cancer Institute-Frederick. | Retrovirology BioMed Central Commentary David D. Derse 1949-2009 Maureen Shuh Open Access Address Division of Basic Pharmaceutical Sciences College of Pharmacy Xavier University of Louisiana New Orleans LA 70125 USA Email Maureen Shuh - mshuh@ Published I December 2009 Received 27 November 2009 Accepted 1 December 2009 Retrovirology 2009 6 110 doi 1742-4690-6- 110 This article is available from http content 6 1 1 10 2009 Shuh licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract David D. Derse . Head of the Retrovirus Gene Expression Section in the HIV Drug Resistance Program at the National Cancer Institute-Frederick NCI-Frederick passed away on October 9 2009 a scant six weeks after being diagnosed with liver cancer. It was with great sadness that family friends and colleagues gathered together for his memorial service on Saturday October 17 2009 at the Middletown United Methodist Church in Maryland. As a NCI scientist since 1986 Dave studied the molecular mechanisms of infection and replication of a number of different types of retroviruses. Dave became an internationally known expert on human T cell lymphotrophic viruses type 1 and 2 HTLV-1 and HTLV-2 and served on the editorial boards of Virology and Retrovirology. His most recent studies focused on the mechanisms of HTLV-1 virion morphogenesis transmission and replication. Background David Daniel Derse was born in Los Angeles California on December 22 1949. After graduating from California State University Northridge with a . in Chemistry in 1973 Dave worked as a research technician at Childrens Hospital Los Angeles from 1974-1977 in the laboratory of Dr. Richard L. Momparler studying the biochemical pharmacology of new
